

RESEARCH

Open Access



# Lp(a), oxidized phospholipids and oxidation-specific epitopes are increased in subjects with keloid formation

Sundeep Ruder<sup>1</sup>, Brett Mansfield<sup>1</sup>, Andrew Ronald Immelman<sup>1</sup>, Nissi Varki<sup>2</sup>, Phuong Miu<sup>3</sup>, Frederick Raal<sup>1\*</sup> and Sotirios Tsimikas<sup>3</sup>

## Abstract

**Background** Keloid formation following trauma or surgery is common among darkly pigmented individuals. Since lipoprotein(a) [Lp(a)] has been postulated to have a putative role in wound healing, and also mediates atherosclerotic cardiovascular disease, it was assessed whether Lp(a), its associated oxidized phospholipids and other oxidation-specific biomarkers were associated with keloid formation.

**Methods** This case-control study included darkly pigmented individuals of African ancestry, 100 with keloid scarring and 100 non-keloid controls. The lipid panel, hsCRP, Lp(a), oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB), IgG and IgM apoB-immune complexes and IgG and IgM autoantibodies to a malondialdehyde mimotope (MDA-mimotope) were measured. Immunohistochemistry of keloid specimens was performed for both Lp(a) and OxPL staining.

**Results** Cases and controls were well matched for age, sex and lipid profile. Mean Lp(a) (57.8 vs. 44.2 mg/dL;  $P=0.01$ , OxPL-apoB 17.4 vs. 15.7 nmol/L;  $P=0.009$ ) and IgG and IgM apoB-immune complexes and IgG and IgM MDA-mimotope levels were significantly higher in keloid cases. Keloid tissue stained strongly for OxPL.

**Conclusion** Darkly pigmented individuals of African ancestry with keloids have higher plasma levels of Lp(a), OxPL-apoB and oxidation-specific epitopes. The commonality of excessive wound healing in keloids and chronic complications from coronary revascularization suggests avenues of investigation to define a common mechanism driven by Lp(a) and the innate response to oxidized lipids.

## Highlights

- Keloid formation is common among individuals of African ancestry.
- Lp(a) and OxPL are associated with acute and chronic CVD events.
- Lp(a) and OxPL-apoB levels are elevated in patients with keloids.
- Keloids express OxPL staining but not Lp(a) staining.
- OxPL on Lp(a) may be mechanistically involved in keloid formation.

\*Correspondence:

Frederick Raal  
Frederick.Raal@wits.ac.za

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## Introduction

Lipoprotein(a) [Lp(a)] is a cholesterol ester-rich low density lipoprotein (LDL)-like particle composed of a single apolipoprotein B100 (apoB) covalently linked to apolipoprotein(a) [1]. Epidemiological and genetic data has provided support for elevated levels of Lp(a) being a risk factor for both atherosclerotic cardiovascular disease (ASCVD) [2–4] and aortic stenosis [5, 6]. Lp(a) is postulated to mediate cardiovascular disease through 3 key mechanisms [7]: inflammation through its content of oxidized phospholipids (OxPL), anti-fibrinolytic effects through its apo(a) component [8] and atherogenicity via its LDL-like component.

A physiological role, if any, of Lp(a) remains undefined. Elevated Lp(a) levels are clearly associated with ASCVD and aortic stenosis, but there have been no other non-cardiovascular phenotypes noted [7]. Conversely, absence of Lp(a), which is rare, has not been associated with any known clinical adverse events [9, 10]. There have been several reports of a higher rate of incident diabetes in subjects with very low Lp(a) levels of <5 mg/dL [11–13], which may represent 10% of the population at large [14], but it has not been established if these are causal or reverse causality effects of insulin resistance resulting in lower Lp(a) levels.

A putative physiological role of Lp(a) is to potentiate rapid wound healing or to prevent excessive bleeding [15]. These presumably occur at a young age or during childbirth and may provide the evolutionary pressure to maintain high levels among some individuals across populations. The apo(a) component of Lp(a) contains several lysine binding sites [16, 17], including a potent one on kringle IV<sub>10</sub> (KIV<sub>10</sub>) that allows apo(a) to bind to denuded endothelium and presumably deliver its cargo of cholesterol and other lipids for cell membrane repair. Indirect evidence for such a role of Lp(a) may be in keloid formation, representing an exaggerated wound healing effect. Keloids are common among darkly pigmented individuals. A previous study has shown that keloids are associated with carotid atherosclerosis but not explained by traditional cardiovascular risk factors [18]. Furthermore, Lp(a) is abundantly present in coronary bypass [19] and both elevated Lp(a) and OxPL in native coronary artery lesions [20] and have also been associated with both acute and long-term adverse outcomes in patients undergoing coronary artery bypass graft (CABG) surgery [21–23] or percutaneous coronary intervention (PCI) [24–26].

A potentially causal link between Lp(a) and the higher prevalence of keloids in this population group is postulated. The aim of this study was, therefore, to measure Lp(a) and their associated OxPL in darkly pigmented African patients with keloids and to determine whether

there is any relationship between Lp(a) and keloid formation.

## Materials and methods

### Study subjects

Two hundred darkly pigmented subjects were recruited, one hundred with obvious keloid scarring and one hundred controls without evidence of keloid scarring. All participants were of black African ancestry, apart from one individual with a history of keloids who was of mixed ancestry. Subjects with keloids were identified at a designated “keloid clinic” run by the Department of Plastic Surgery, Faculty of Health Sciences, University of the Witwatersrand. Many of the keloids had developed following ear piercing or shaving and because of being located on the face the patients requested removal. The time between the injury and the onset of keloid scarring was not recorded. Black African control subjects of the same sex and within 5 years of age with previous surgery/trauma and no keloid development were enrolled.

### Laboratory variables

After informed consent 20mL blood was drawn from a cubital vein. Total cholesterol, triglycerides, high density lipoprotein cholesterol (HDL-C) calculated low density lipoprotein cholesterol (LDL-C), high sensitivity-C-reactive protein (hsCRP) and serum creatinine were measured using standard assays.

### Measurement of *lp(a)*, oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) and other oxidation-specific epitopes

Lp(a) [27], OxPL-apoB [28], IgG and IgM apoB-immune complexes [29] and IgG and IgM autoantibodies to a malondialdehyde mimotope (MDA-mimotope) [30] were measured by using in house chemiluminescent enzyme-linked immunosorbent assays (ELISA) developed at the University of California San Diego as previously described.

### Immunohistochemistry of keloid tissue

Details of immunohistochemical techniques to stain for the apolipoprotein(a) component of Lp(a) with murine monoclonal antibody LPA4, developed at UCSD [27], OxPL epitopes with murine monoclonal antibody E06 and apoB-100 with murine monoclonal antibody MB47 have been previously described [20, 29, 31]. In brief, keloid tissues were paraffin embedded, cut into 7 μm thick sections and mounted on charged slides. The sections were deparaffinized with HistoClear and rehydrated through graded ethanol. For antigen retrieval, sections were incubated with Sodium Citrate buffer (pH 6.0) in water bath at 95–100 °C for 20 min, then blocked with 5% normal goat serum/1% BSA/TBS for 30 min at room

**Table 1** Baseline characteristics of the study groups

Variable	Keloid cases (n = 100)	Controls (n = 100)	P-value
Age (years)	27 (22, 34.5)	29 (23, 37.5)	0.20
Females (%)	40	44	0.57
Weight (kg)	70.5 (60.0, 81.0)	74.0 (62.5, 85.5)	0.26
Family history of keloids (%)	13	0	<0.0001
Smokers (%)	2	8	0.05
Previous cardiac event (%)	0	1	0.32
Total cholesterol (mmol/L)	4.12 ± 0.88	4.30 ± 0.89	0.15
HDL-cholesterol (mmol/L)	1.40 ± 0.36	1.40 ± 0.36	0.91
LDL-cholesterol (mmol/L)	2.48 ± 2.00	2.40 ± 0.79	0.78
Triglycerides (mmol/L)	0.99 ± 0.98	1.09 ± 0.60	0.03
hsCRP (mg/dL)	1.20 (0.57, 3.84)	1.28 (0.57, 3.58)	0.66
Creatinine (μmol/L)	65.2 ± 15.4	74.2 ± 16.4	<0.0001
eGFR (mL/min/1.73m <sup>2</sup> )	138 (116, 166)	122 (103, 149)	<0.0001

Data are presented as percentages (%), mean ± SD or median (IQR)

temperature. Monoclonal antibodies LPA4, E06 and MB47 diluted with blocking buffer to 5 μg/ml were used to stain sections in a humidified chamber at 4 °C overnight to detect apolipoprotein(a), OxPL and apoB-100, respectively. Sections were then incubated with an anti-mouse IgG-alkaline phosphatase (Sigma A3438) diluted with blocking buffer at 1:50 for 30 min at room temperature, and then visualized with Vector Red substrate (Vector SK-5100). Sections were counterstained with hematoxylin for 30 s and mounted with Simpo-Mount (IHCWorld EO3-18). Immunostaining of consecutive sections in the absence of primary Abs was used as a negative control. Images were captured with Hamamatsu Nanozoomer 2.0HT slide scanner with a 20X lens.

The methodology for immunostaining for apolipoprotein(a) is established and uses murine monoclonal antibody LPA4 that detects the 14-amino acid epitope TRNYCRNPDAEIRP present on KIV<sub>5</sub>, KIV<sub>7</sub> and KIV<sub>8</sub> of apolipoprotein(a), and also detects the partial sequence of NYCRNPDA present on KIV<sub>2</sub>. Furthermore, LPA4 has been used widely in the past and heavily stains apo(a) in coronary, carotid and aortic valve tissues [20, 31]. In addition, it was also used in the ELISA used to document the higher Lp(a) levels in subjects with keloids in this study.

#### Statistical analyses

Data were analyzed using Statistica, version 13.3.0, June 2017, licensed through the University of the Witwatersrand. Standard descriptive statistics were used to describe the data for continuous variables (mean, median, range and standard deviation), and numbers and percentages were used for categorical variables. The Kolmogorov-Smirnov and Shapiro-Wilk tests were used

**Table 2** Levels of Lp(a), OxPL-apoB and oxidation-specific biomarkers in cases and controls

Variable	Keloid cases (n = 100)	Controls (n = 100)	P-value
Lp(a) (mg/dL)	57.8 (34.7, 93.5)	44.2 (20.8, 72.3)	0.01
OxPL-apoB (nmol/L)	17.4 (14.3, 20.9)	15.7 (12.6, 19.3)	0.009
IgG MDA-mimotope, RLU	607 (408, 853)	422 (311, 639)	0.001
IgM MDA-mimotope, RLU	1512 (997, 2424)	1346 (857, 1923)	0.02
IgG ApoB-IC, RLU	1291 (916, 1764)	888 (691, 1184)	<0.0001
IgM ApoB-IC, RLU	1404 (1010, 1997)	814 (574, 1185)	<0.0001

Data represented as medians and interquartile ranges

to assess normality of the distribution of the data. For normally distributed data, 1-way ANOVA and unpaired Student t tests were used to compare differences between the groups, and for skewed data, the Mann-Whitney U test was used. Significance was defined as  $P < 0.05$ .

## Results

### Baseline characteristics

Table 1 displays the baseline characteristics of the study groups. There were no significant differences in mean age (27 vs. 29 years), sex (40% vs. 44% females) or weight (70.5 vs. 74.0 kg) between the cases and controls. Notably, there was a higher family history incidence of keloid in cases (13% vs. 0%) than controls. There were no significant differences in the lipid profiles or hsCRP, but cases had lower creatinine and higher eGFR than controls.

### Lp(a), oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) and other oxidation-specific epitopes

Table 2 displays the levels of Lp(a), OxPL-apoB and oxidation-specific biomarkers in cases and controls. Both baseline Lp(a) (normal < 30 mg/dL) and OxPL-apoB (> 75th percentile is > 7.5 nmol/L) levels were elevated in both keloid cases and controls. However, compared to controls, keloid cases had higher levels of Lp(a) (57.8 vs. 44.2 mg/dL;  $P = 0.01$ ), OxPL-apoB (17.4 vs. 15.7 nmol/L;  $P = 0.009$ ), IgG MDA-mimotope titers (607 vs. 422 RLU,  $P = 0.001$ ), IgM MDA-mimotope titers (1512 vs. 1346 RLU,  $P = 0.001$ ), IgG ApoB-IC titers (1291 vs. 888 RLU,  $P < 0.0001$ ) and IgM MDA-mimotope titers (1404 vs. 814 RLU,  $P < 0.0001$ ).

### Immunohistochemistry of keloid tissue

Representative sections of keloid immunostaining are shown in the Fig. 1. Staining of keloid tissue with von Giesen stain revealed significant amounts of collagen (Fig. 1, panel A, red) in a highly cellular specimen (blue). Interestingly, there was no evidence for the presence of apolipoprotein(a) in keloid tissue (Fig. 1, panel B). However, there was significant amount of E06-detectable OxPL (Fig. 1, panel C, red), which appeared to be in more

cellular areas and less so in areas of abundant collagen. Very faint staining for human apoB-100 was also present (Fig. 1, panel D, red). A higher resolution image of the OxPL staining is shown in the Fig. 1, panel E. The no antibody control did not reveal any staining (not shown).

### Correlations among biomarkers

In the combined groups, Lp(a) was strongly correlated with OxPL-apoB ( $r=0.79$ ,  $P<0.0001$ ), and more modestly with IgG and IgM apoB-IC and MDA-mimotope (Table 3). The correlation coefficients were similar between keloid cases and non-keloid controls.

### Discussion

This study demonstrates that darkly pigmented African subjects with keloid formation had significantly higher levels of Lp(a), OxPL-apoB, circulating IgG and IgM apoB-immune complexes and MDA-mimotope levels compared to the non-keloid control group. Second, the presence of E06-detectable OxPL within keloid scars was documented by immunostaining. The commonality of excessive wound healing in keloids and certain aspects of CABG and PCI that lead to vessel occlusion suggests avenues of investigation to define common mechanisms driven by Lp(a) and the innate response to oxidized lipids. It is estimated that 100 million patients develop scars in the developed world alone each year following surgery or trauma [32]. As opposed to excessive hypertrophic scar formation, keloids typically project beyond the original wound margins.


The prevalence of elevated Lp(a), defined as  $>75$  nmol/L ( $\sim>30$  mg/dL) is approximately 20% of the population, or 1.5 billion people [33]. In this study, Lp(a) levels in both groups were higher than what is considered normal by most clinical laboratories. However, it is known that Lp(a) levels are 2–4 times higher in people of African descent compared to Caucasians [34, 35]. As opposed to most other racial/ethnic groups, darkly pigmented individuals of African descent tend to have higher population mean Lp(a) levels despite not necessarily having small isoforms, as documented in the Dallas Heart Study in US African Americans [35], suggesting additional unknown influences on apolipoprotein(a) expression and/or clearance. In the current study, despite the overall increased Lp(a) levels, the subjects with keloid formation had significantly higher Lp(a) levels. Keloid formation appears to be genetically determined as well, as suggested by the significant proportion of these subjects with keloids who also had a family history of keloid.

The higher circulating levels of OxPL-apoB in both groups may be related to the fact that the main lipoprotein carrier of OxPL, Lp(a), was also elevated. In prior studies, the 75th percentile for population cutoffs of OxPL-apoB are  $>7.5$  nmol/L [28, 36–38], but patients

with elevated Lp(a) have significantly higher levels, often exceeding  $>20$  nmol/L [39, 40]. These findings were replicated in this study, but the subjects with keloid had even higher levels than the no-keloid controls. The findings on OxPL-apoB were complimented and consistent with the data on autoantibodies to MDA-mimotope and apoB-immune complexes, which generally reflect innate and adaptive immune activation awareness of the presence of pro-inflammatory oxidation specific epitopes. These biomarkers have often been associated with cardiovascular risk. For example, in epidemiological studies in stable patients, the IgG autoantibodies to oxidation-specific epitopes are positively associated with higher cardiovascular risk, but the IgM autoantibodies to oxidation-specific epitopes, which tend to be natural antibodies present at birth, seem to be protective [41]. In contrast, in more acute situations such as acute coronary syndromes and percutaneous coronary interventions, they tend to risk in parallel [27, 42]. The fact that both IgG and IgM biomarkers are higher in subjects with keloids suggests persistent immune activation to oxidation specific epitopes.

The immunohistochemistry data showed only faint apoB staining and could not identify the presence of apolipoprotein(a) in keloid tissue, suggesting that the Lp(a) holoparticle was not accumulating to any significant extent in the keloid tissue. In contrast, immunostaining for OxPL was present widely, but not necessarily strongest in areas of dense collagen deposition. Whether these OxPL are derived from the plasma or are generated by cells in situ within keloids cannot be determined from this study. In prior studies in mouse models which did not have the Lp(a) transgene or in cynomolgus monkeys which had Lp(a) but no associated OxPL due to variations in the KIV<sub>10</sub> lysine binding pocket, OxPL could be documented to both accumulate and regress in response to high fat/cholesterol or regression diets, respectively [43, 44]. Finally, in human atheromata and aortic valve leaflets, Lp(a) and OxPL do not necessarily always co-localize, suggesting that OxPL can be derived from additional sources besides Lp(a), such as apoptotic cells, cell membrane oxidation and other lipoproteins [20, 31].

There are additional clinical phenotypes that might be considered a response to injury, such as atherosclerosis, acute plaque rupture and restenosis in response to balloon angioplasty and stent placement, where Lp(a) may play a role [43, 45]. Recent studies suggest elevated Lp(a) levels are associated with chronic complications for PCI, both within the stent and adjacent to it, suggesting neo-atherosclerosis. For example, a prospective single-center registry of 12,064 patients undergoing PCI showed that 31.1% of patients had Lp(a) levels  $>30$  mg/dL [24]. During a median follow-up of 7.4 years, the primary outcome, a composite of cardiovascular death, spontaneous myocardial infarction, and ischemic stroke, and repeated



**Fig. 1** Representative sections of keloid immunostaining for Lp(a) and OxPL. Panel A represents von Gieson stain revealing significant amounts of collagen (red) in a highly cellular specimen (blue). Panel B represents immunostaining for apolipoprotein(a), which is not visible. Panel C represents immunostaining for E06-detectable OxPL (red) and panel E represents the inset at higher resolution. Panel D immunostaining for human apoB-100 (red). Bar = 500 μm

**Table 3** Correlations between Lp(a) and laboratory variables

Variables	Combined groups (N = 200)	Non-keeloid controls (n = 100)	Keeloid cases (n = 100)
Total cholesterol	0.14 (0.16)	0.13 (0.21)	0.20 (0.046)
LDL-cholesterol	0.17 (0.09)	0.17 (0.08)	0.18 (0.08)
OxPL-apoB	0.79 ( $< 0.0001$ )	0.82 ( $< 0.0001$ )	0.75 ( $< 0.0001$ )
IgG MDA-Mimotope	0.26 (0.009)	0.27 (0.008)	0.22 (0.028)
IgM MDA-Mimotope	0.09 (0.34)	0.12 (0.22)	0.05 (0.64)
IgG ApoB-IC	0.04 (0.68)	-0.04 (0.70)	0.006 (0.95)
IgM ApoB-IC	0.09 (0.33)	0.03 (0.73)	0.03 (0.77)

Data given as  $r$  ( $P$ -value) for correlations with levels of Lp(a). Associations were tested using Pearson correlation with skewed variables first being normalised via log transformation or use of square roots (Lp(a)). No other variables correlated with Lp(a)

revascularization was significantly higher in the high Lp(a) group. Similarly, elevated Lp(a) and low molecular-weight apo(a) phenotype were independently associated with three-fold increase in risk of major adverse cardiovascular events within 15 years after CABG [23]. Mechanistically, the apo(a) component of Lp(a), which carries significant OxPL on KIV<sub>10</sub>, has been shown to stimulate smooth muscle cell proliferation and migration in a TGF- $\beta$  dependent process [46, 47]. These clinical phenotypes are considerably enriched in Lp(a)/OxPL, and specifically in advanced or ruptured plaques [20], chronic total occlusions [48], and in acute coronary syndromes [42] and PCI [27]. Direct evidence is also shown by the capture of plaque debris from carotid, coronary, renal and saphenous vein graft interventions, documenting the presence of OxPL [49].

### Strengths and limitations

This study is novel in that no other studies have examined the association between Lp(a) and keloid formation. A limitation of this study is that it is observational and cannot be used as evidence of causality. Additional studies are required to confirm and expand on these findings. Furthermore, apo(a) isoforms were not measured in this study and may have provided additional insights into the observations. Finally, whether these findings pertain to individuals who are lightly pigmented is not known and requires further study.

### Conclusion

In conclusion, darkly pigmented African individuals with keloids have higher plasma levels of Lp(a), OxPL-apoB and indirect biomarkers of oxidation-specific epitopes and higher levels of OxPL in keloid tissue. Given the relationship between raised Lp(a) and ASCVD, the presence of keloid formation may be an indicator of individuals at greater risk for ASCVD, however, these observations require additional study to determine whether a causal relationship exists.

### Abbreviations

OxPL	Oxidized phospholipids
Lp(a)	Lipoprotein(a)
MDA	Malondialdehyde
ASCVD	Atherosclerotic cardiovascular disease
CABG	Coronary artery bypass graft
PCI	Percutaneous coronary intervention
IgG	Immunoglobulin G
IgM	Immunoglobulin M
ApoB-IC	ApoB immune complex
K	Kringles
eGFR	Estimated glomerular filtration rate
RLU	Relative light units

### Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12944-022-01720-z>.

Supplementary Material 1

### Acknowledgements

Not applicable.

### Authors' contributions

SR, BM, ARI conducted the study design and data collection, analysis and drafting of the manuscript. NV and PM performed the immunostaining and/or biomarker assays. FR and ST conducted the study design, analysis and drafting of the first version of the manuscript.

### Funding

This study was supported by NIH R01 HL159156 (ST).

### Data availability

The datasets generated and/or analyzed during the current study are not publicly available due to confidentiality reasons but are available from the corresponding author on reasonable request.

### Declarations

#### Ethics approval and consent to participate

The study was by the ethics committee of the University of the Witwatersrand.

#### Consent for publication

All authors contributed significantly to the manuscript for intellectual content and provided consent for publication.

#### Competing interests

ST is a co-inventor and receives royalties from patents owned by UCSD on oxidation-specific antibodies and of biomarkers related to oxidized lipoproteins, is a co-founder and has an equity interest in Oxitope, Inc and its affiliates ("Oxitope"), Kleanthi Diagnostics, LLC ("Kleanthi") and Covicept Therapeutics. Although these relationships have been identified for conflict of interest management based on the overall scope of the project and its potential benefit to Oxitope and Kleanthi, the research findings included in this particular publication may not necessarily relate to the interests of Oxitope and Kleanthi. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. The other authors have no conflicts.

#### Author details

<sup>1</sup>Carbohydrate & Lipid Metabolism Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

<sup>2</sup>Department of Pathology, University of California, San Diego, USA

<sup>3</sup>Sulpizio Cardiovascular Center, Division of Cardiovascular Medicine, University of California, 9500 Gilman Drive, 92093-0682 San Diego, USA

Received: 15 September 2022 / Accepted: 6 October 2022

Published online: 01 November 2022

## References

- Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein(a). *J Lipid Res.* 2016;57(8):1339–59.
- Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, et al. Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. *JAMA.* 2009;302(4):412–23.
- Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. *N Engl J Med.* 2009;361(26):2518–28.
- Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. *JAMA.* 2009;301(22):2331–9.
- Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, et al. Genetic associations with valvular calcification and aortic stenosis. *N Engl J Med.* 2013;368(6):503–12.
- Capoulade R, Chan KL, Yeang C, Mathieu P, Bosse Y, Dumesnil JG, et al. Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis. *J Am Coll Cardiol.* 2015;66(11):1236–46.
- Tsimikas S. A test in context: Lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. *J Am Coll Cardiol.* 2017;69(6):692–711.
- Boffa MB, Koschinsky ML. Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? *J Lipid Res.* 2016;57(5):745–57.
- Lim ET, Wurtz P, Havulinna AS, Palta P, Tukiainen T, Rehnstrom K, et al. Distribution and medical impact of loss-of-function variants in the Finnish founder population. *PLoS Genet.* 2014;10(7):e1004494.
- Emdin CA, Khera AV, Natarajan P, Klarin D, Won HH, Peloso GM, et al. Phenotypic characterization of genetically lowered human lipoprotein(a) levels. *J Am Coll Cardiol.* 2016;68(25):2761–72.
- Mora S, Kamstrup PR, Rifai N, Nordestgaard BG, Buring JE, Ridker PM. Lipoprotein(a) and risk of type 2 diabetes. *Clin Chem.* 2010;56(8):1252–60.
- Kamstrup PR, Nordestgaard BG. Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study. *Lancet Diabetes Endocrinol.* 2013;1(3):220–7.
- Ye Z, Haycock PC, Gurdasani D, Pomilla C, Boekholdt SM, Tsimikas S, et al. The association between circulating lipoprotein(a) and type 2 diabetes: is it causal? *Diabetes.* 2014;63(1):332–42.
- Varvel S, McConnell JP, Tsimikas S. Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 Patients in the United States. *Arterioscler Thromb Vasc Biol.* 2016;36(11):2239–45.
- Brown MS, Goldstein JL. Plasma lipoproteins: teaching old dogmas new tricks. *Nature.* 1987;330(6144):113–4.
- McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. *Nature.* 1987;330(6144):132–7.
- Hoover-Plow JL, Miles LA, Fless GM, Scanu AM, Plow EF. Comparison of the lysine binding functions of lipoprotein(a) and plasminogen. *Biochemistry.* 1993;32(49):13681–7.
- Bhavsar S, Nimigan A, Hackam DG, O’Gorman DB, Gan BS, Spence JD. Keloid scarring, but not Dupuytren’s contracture, is associated with unexplained carotid atherosclerosis. *Clin Invest Med Clinique et experimentale.* 2009;32(2):E95–102.
- Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. *Arteriosclerosis.* 1989;9(5):579–92.
- van Dijk RA, Kolodgie F, Ravandi A, Leibundgut G, Hu PP, Prasad A, et al. Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. *J Lipid Res.* 2012;53(12):2773–90.
- Skinner JS, Farrer M, Albers CJ, Piper K, Neil HA, Adams PC. Serum Lp(a) lipoprotein concentration is not associated with clinical and angiographic outcome five years after coronary artery bypass graft surgery. *Heart.* 1997;78(2):131–5.
- Kwon SW, Lee BK, Hong BK, Kim JY, Choi EY, Sung JM, et al. Prognostic significance of elevated lipoprotein(a) in coronary artery revascularization patients. *Int J Cardiol.* 2013;167(5):1990–4.
- Ezhov MV, Safarova MS, Afanasieva OI, Kukharchuk VV, Pokrovsky SN. Lipoprotein(a) level and apolipoprotein(a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting. *Atherosclerosis.* 2014;235(2):477–82.
- Yoon Y-H, Ahn J-M, Kang D-Y, Lee PH, Kang S-J, Park D-W, et al. Association of lipoprotein(a) with recurrent ischemic events following percutaneous coronary intervention. *JACC: Cardiovasc Interv.* 2021;14(18):2059–68.
- Park SH, Rha SW, Choi BG, Park JY, Jeon U, Seo HS, et al. Impact of high lipoprotein(a) levels on in-stent restenosis and long-term clinical outcomes of angina pectoris patients undergoing percutaneous coronary intervention with drug-eluting stents in Asian population. *Clin Exp Pharmacol Physiol.* 2015;42(6):588–95.
- Kardys I, Oemrawsingh RM, Kay IP, Jones GT, McCormick SP, Daemen J, et al. Lipoprotein(a), interleukin-10, C-reactive protein, and 8-year outcome after percutaneous coronary intervention. *Clin Cardiol.* 2012;35(8):482–9.
- Tsimikas S, Lau HK, Han KR, Shortal B, Miller ER, Segev A, et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. *Circulation.* 2004;109(25):3164–70.
- Bertoia ML, Pai JK, Lee JH, Taleb A, Joosten MM, Mittleman MA, et al. Oxidation-specific biomarkers and risk of peripheral artery disease. *J Am Coll Cardiol.* 2013;61(21):2169–79.
- Ravandi A, Boekholdt SM, Mallat Z, Talmud PJ, Kastelein JJ, Wareham NJ, et al. Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. *J Lipid Res.* 2011;52(10):1829–36.
- Amir S, Hartvigsen K, Gonen A, Leibundgut G, Que X, Jensen-Jarolim E, et al. Peptide mimotopes of malondialdehyde epitopes for clinical applications in cardiovascular disease. *J Lipid Res.* 2012;53(7):1316–26.
- Torzewski M, Ravandi A, Yeang C, Edel A, Bhindi R, Kath S, et al. Lipoprotein(a) associated molecules are prominent components in plasma and valve leaflets in calcific aortic valve stenosis. *JACC Basic Transl Sci.* 2017;2(3):229–40.
- Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. *Mol Med.* 2011;17(1–2):113–25.
- Tsimikas S, Marcovina SM. Ancestry, lipoprotein(a), and cardiovascular risk thresholds: JACC Review Topic of the Week. *J Am Coll Cardiol.* 2022;80(9):934–46.
- Marcovina SM, Zhang ZH, Gaur VP, Albers JJ. Identification of 34 apolipoprotein(a) isoforms: differential expression of apolipoprotein(a) alleles between American blacks and whites. *Biochem Biophys Res Commun.* 1993;191(3):1192–6.
- Tsimikas S, Clopton P, Brilakis ES, Marcovina SM, Khera A, Miller ER, et al. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. *Circulation.* 2009;119(13):1711–9.
- Byun YS, Lee JH, Arsenault BJ, Yang X, Bao W, DeMicco D, et al. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. *J Am Coll Cardiol.* 2015;65(13):1286–95.
- Byun YS, Yang X, Bao W, DeMicco D, Laskey R, Witztum JL, et al. Oxidized phospholipids on apolipoprotein B-100 and recurrent ischemic events following stroke or transient ischemic attack. *J Am Coll Cardiol.* 2017;69(2):147–58.
- Tsimikas S, Duff GW, Berger PB, Rogus J, Huttner K, Clopton P, et al. Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a). *J Am Coll Cardiol.* 2014;63(17):1724–34.
- Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. *Lancet.* 2016;388(10057):2239–53.
- Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. *N Engl J Med.* 2020;382(3):244–55.
- Binder CJ. Lipid modification and lipid peroxidation products in innate immunity and inflammation. *Biochim Biophys Acta.* 2017;1862(4):369–70.
- Tsimikas S, Bergmark C, Beyer RW, Patel R, Pattison J, Miller E, et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. *J Am Coll Cardiol.* 2003;41(3):360–70.
- Torzewski M, Shaw PX, Han KR, Shortal B, Lackner KJ, Witztum JL, et al. Reduced in vivo aortic uptake of radiolabeled oxidation-specific antibodies reflects changes in plaque composition consistent with plaque stabilization. *Arterioscler Thromb Vasc Biol.* 2004;24(12):2307–12.

44. Tsimikas S, Aikawa M, Miller FJ Jr, Miller ER, Torzewski M, Lentz SR, et al. Increased plasma oxidized phospholipid:apolipoprotein B-100 ratio with concomitant depletion of oxidized phospholipids from atherosclerotic lesions after dietary lipid-lowering: a potential biomarker of early atherosclerosis regression. *Arterioscler Thromb Vasc Biol.* 2007;27(1):175–81.
45. Virmani R, Farb A, Burke AP. Coronary angioplasty from the perspective of atherosclerotic plaque: morphologic predictors of immediate success and restenosis. *Am Heart J.* 1994;127(1):163–79.
46. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. *Nature.* 1994;370(6489):460–2.
47. O'Neil CH, Boffa MB, Hancock MA, Pickering JG, Koschinsky ML. Stimulation of vascular smooth muscle cell proliferation and migration by apolipoprotein(a) is dependent on inhibition of transforming growth factor-beta activation and on the presence of kringle IV type 9. *J Biol Chem.* 2004;279(53):55187–95.
48. Fefer P, Tsimikas S, Segev A, Sparkes J, Otsuka F, Kolodgie F, et al. The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularization. *Cardiovasc Revasc Med.* 2012;13(1):11–9.
49. Ravandi A, Leibundgut G, Hung MY, Patel M, Hutchins PM, Murphy RC, et al. Release and capture of bioactive oxidized phospholipids and oxidized cholesteryl esters during percutaneous coronary and peripheral arterial interventions in humans. *J Am Coll Cardiol.* 2014;63(19):1961–71.

### **Publisher's note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.